
Opinion|Videos|September 30, 2024
Perspectives on Latest Therapies: Faricimab and Aflibercept 8mg
Author(s)Nikolas London, MD, FACS
Fact checked by: Nikolas London, MD, FACS
Dr. London discusses the implications of faricimab and aflibercept 8 mg in treating retinal diseases, highlighting their mechanisms, efficacy data, and potential to enhance patient outcomes in conditions like wet age-related macular degeneration.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
UPDATE: STAAR postpones Alcon merger vote, Broadwood calls for removal of board members
2
Advancements in femtosecond laser technology benefit surgeons and patients
3
Research supports that iron dysregulation may drive AMD
4
ONL Therapeutics randomizes first patient in phase 2 GALAXY trial evaluating xelafaslatide
5













































.png)


